A Phase I Trial of Olanzapine (Zyprexa) for the Prevention of Delayed Emesis in Cancer Patients: A Hoosier Oncology Group Study
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Chemotherapy-induced delayed emesis (DE) can affect up to 50% to 70% of patients receiving moderately and highly emetogenic chemotherapy, although rates are improving. DE most commonly occurs within the first 24 to 48 hours of chemotherapy administration and can persist for 2 to 5 days. Olanzapine, due to its activity at multiple dopaminergic, serotonergic, muscarinic, and histaminic receptor sites, has potential as antiemetic therapy. A phase I study was designed with olanzapine, using a four-cohort dose escalation of 3 to 6 patients per cohort, for the prevention of DE in cancer patients receiving their first cycle of chemotherapy consisting of cyclophosphamide, doxorubicin, platinum, and/or irinotecan. All patients received standard premedication. Olanzapine was administered on days -2 and -1 prior to chemotherapy and continued for 8 days (days 0-7). Episodes of vomiting as well as daily measurements of nausea, sedation, and toxicity were monitored at each dose level. Fifteen patients completed the protocol. No grade 4 toxicities were seen, and three patients experienced a dose-limiting toxicity (grade 3) of a depressed level of consciousness during the study. The maximum tolerated dose appeared to be 5 mg (for days -2 and -1) and 10 mg (for days 0-7). Four of six patients receiving highly emetogenic chemotherapy (cisplatin, > or = 70 mg/m2) and nine of nine patients receiving moderately emetogenic chemotherapy (doxorubicin, > or = 50 mg/m2) had complete control (no vomiting episodes) of DE. Therefore, olanzapine may be an effective agent for the prevention of chemotherapy-induced DE. A phase II trial is underway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Passik, S. D., Lundberg, J., Kirsh, K. L., Theobald, D., Donaghy, K., Holtsclaw, E., Cooper, M., & Dugan, W. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00391-3 · Cited by 154
Self-citation
Cited by
Bloechl-Daum, B., Deuson, R. R., Mavros, P., Hansen, M., & Herrstedt, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.6382 · Cited by 497
Olanzapine for the prevention of chemotherapy-induced nausea and vomiting.
Navari, R. M., Qin, R., Ruddy, K. J., Liu, H., Powell, S. F., Bajaj, M., Dietrich, L., Biggs, D., Lafky, J. M., & Loprinzi, C. L. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515725 · Cited by 452
Self-citationOlanzapine for intractable nausea in palliative care patients.
Jackson, W. C., & Tavernier, L. (2003) · Journal of Palliative Medicine · doi:10.1089/109662103764978506 · Cited by 78
Olanzapine for nausea and vomiting.
Licup, N., & Baumrucker, S. (2010) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909110369532 · Cited by 23
“In all, 3 patients had dose-limiting grade III toxicity secondary to depressed level of consciousness.(13) A phase II trial was completed in 2005, which was on olanzapine in the prevention of CINV.”
BackgroundHarder, S., Groenvold, M., Isaksen, J., Sigaard, J., Frandsen, K. B., Neergaard, M. A., Mondrup, L., & Herrstedt, J. (2019) · Supportive Care in Cancer · doi:10.1007/s00520-018-4593-3 · Cited by 17
Metadata
- Authors
- Passik, S. D., Navari, R. M., Jung, S.-H., Nagy, C., Vinson, J., Kirsh, K. L., & Loehrer, P.
- Venue
- Cancer Investigation
- Publisher
- Informa UK Limited
- Published
- 2004-01
- Volume
- 22
- Issue
- 3
- Pages
- 383-388
- ISSN
- 0735-7907 (ISSN-L)
- 1532-4192
- OpenAlex
- W2045951807
- Cited by
- 102
- References
- 2
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Phase I Trial of Olanzapine (Zyprexa) for the Prevention of Delayed Emesis in Cancer Patients: A Hoosier Oncology Group Study. https://app.cochat.ai/papers/10.1081/cnv-200029066
- The paper
- Passik, S. D., Navari, R. M., Jung, S.-H., Nagy, C., Vinson, J., Kirsh, K. L., & Loehrer, P. (2004). A Phase I Trial of Olanzapine (Zyprexa) for the Prevention of Delayed Emesis in Cancer Patients: A Hoosier Oncology Group Study. Cancer Investigation. https://doi.org/10.1081/cnv-200029066
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.